Literature DB >> 18690846

The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion.

Yih-Wen Chen1, Christina Tekle, Oystein Fodstad.   

Abstract

The monoclonal antibody (mAb) 376.96 has been used for detection of micrometastatic tumor cells due to its high binding specificity for a wide range of tumor cells, but the identity and function of its target antigen have not been known. Here, using immunoprecipitation and siRNA technology, we demonstrate that the antigen is the human 4Ig-B7H3 (4Ig-hB7H3) protein, previously known as an immunoregulatory protein in immune cells. Immunoblots of whole cell lysates, subcellular fractionation and tunicamycin treatment of human tumor cells indicated that 4Ig-hB7H3 is a approximately 100-kDa N-linked glycosylated membrane protein. The tumor promoter phorbol 12-myristate 13-acetate (PMA) enhanced the expression of 4Ig-hB7H3 in FEMX-I (melanoma), MA11 (breast cancer), and OHS (osteosarcoma) cells, suggesting that 4Ig-hB7H3 may be implicated in tumorigenesis. Most importantly, siRNA-downregulation of hB7H3 reduced cell adhesion to fibronectin of melanoma and breast cancer cells by up to 50 %, and migration and matrigel-invasion by more than 70 %, but surprisingly had no apparent impact on cell proliferation. In conclusion, our data present 4Ig-hB7H3 as a tumor-associated antigen and suggests a novel biological role of 4Ig-hB7H3 in tumor progression and metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18690846     DOI: 10.2174/156800908785133141

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  43 in total

1.  B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.

Authors:  Hao Liu; Christina Tekle; Yih-Wen Chen; Alexandr Kristian; Yuhua Zhao; Ming Zhou; Zixing Liu; Yan Ding; Bin Wang; Gunhild Mari Mælandsmo; Jahn Marthin Nesland; Oystein Fodstad; Ming Tan
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

Review 2.  B7-H3 role in the immune landscape of cancer.

Authors:  Jose R Castellanos; Ian J Purvis; Collin M Labak; Maheedhara R Guda; Andrew J Tsung; Kiran K Velpula; Swapna Asuthkar
Journal:  Am J Clin Exp Immunol       Date:  2017-06-15

3.  Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.

Authors:  Hiroko Kobori; Masaaki Hashiguchi; Jinhua Piao; Moriyuki Kato; Patcharee Ritprajak; Miyuki Azuma
Journal:  Immunology       Date:  2010-02-05       Impact factor: 7.397

4.  Expression levels of B7-H3 and TLT-2 in human oral squamous cell carcinoma.

Authors:  Shan-Shan Zhang; Jing Tang; Shu-Yi Yu; L I Ma; Feng Wang; Shu-LE Xie; Long Jin; Hong-Yu Yang
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

5.  Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1α.

Authors:  Sangbin Lim; Hao Liu; Luciana Madeira da Silva; Ritu Arora; Zixing Liu; Joshua B Phillips; David C Schmitt; Tung Vu; Steven McClellan; Yifeng Lin; Wensheng Lin; Gary A Piazza; Oystein Fodstad; Ming Tan
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

6.  Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.

Authors:  Elodie Picarda; Kim C Ohaegbulam; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2016-05-20       Impact factor: 12.531

7.  Plasma miR-940 may serve as a novel biomarker for gastric cancer.

Authors:  Xin Liu; Ava Kwong; Alan Sihoe; Kent-Man Chu
Journal:  Tumour Biol       Date:  2015-10-11

8.  The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Authors:  Martin A Cheever; James P Allison; Andrea S Ferris; Olivera J Finn; Benjamin M Hastings; Toby T Hecht; Ira Mellman; Sheila A Prindiville; Jaye L Viner; Louis M Weiner; Lynn M Matrisian
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531

9.  CSPG4 as a prognostic biomarker in chordoma.

Authors:  Andrew J Schoenfeld; Xinhui Wang; Yangyang Wang; Francis J Hornicek; G Petur Nielsen; Zhenfeng Duan; Soldano Ferrone; Joseph H Schwab
Journal:  Spine J       Date:  2015-12-09       Impact factor: 4.166

10.  MicroRNA miR-29a Inhibits Colon Cancer Progression by Downregulating B7-H3 Expression: Potential Molecular Targets for Colon Cancer Therapy.

Authors:  Jin Wang; Xiaojuan Chen; Chen Xie; Mingbing Sun; Chenrui Hu; Zhe Zhang; Lipeng Luan; Jin Zhou; Jian Zhou; Xinguo Zhu; Jun Ouyang; Xiaoqiang Dong; Dechun Li; Jianglei Zhang; Xin Zhao
Journal:  Mol Biotechnol       Date:  2021-06-07       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.